Cingulate Inc. reported a net loss of $6.0 million for the third quarter of 2025, compared to a net loss of $3.3 million in the same period in 2024. For the nine months ended September 30, 2025, the net loss was $14.4 million, up from $9.4 million in the prior year period. Research and development expenses for the quarter were $2.8 million, and general and administrative expenses were $3.1 million, both higher than the previous year. As of September 30, 2025, cash and cash equivalents totaled $6.1 million, with total assets at $10.5 million and stockholders' equity at $3.5 million. During the period, the FDA accepted Cingulate's New Drug Application for CTx-1301, with a Prescription Drug User Fee Act (PDUFA) date set for May 31, 2026. The company also completed a $6.6 million financing transaction through a non-convertible, unsecured promissory note.